Canada clears Uroplasty's next-generation bladder device:
This article was originally published in Clinica
Executive Summary
Canadian regulators have given Uroplasty the all-clear to sell a next-generation version of its Urgent PC neuromodulation system for treating overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. The redesigned product comprises enhanced controls, visual and auditory signals of operational status and an ergonomic device shape, the Minnetonka, Minnesota firm said, adding that Canada was the first country to approve the new system. The ergonomic design and enhanced user interface offers clinicians ease of use, while effectively delivering percutaneous tibial nerve stimulation therapy, the company noted.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.